CareDx, Inc. has completed the sale of its Lab Products business to Eurobio Scientific for $171.2 million in cash, sharpening its focus on U.S. precision medicine Testing Services and Patient & Digital Solutions. The transaction, which closed on June 30, 2026, followed the receipt of required Swedish regulatory clearance. This strategic move allows CareDx to streamline its operating model and concentrate on high-value healthcare solutions for transplant patients and caregivers.

Transaction Details

Under the terms of the agreement, CareDx received $171.2 million in cash consideration at closing, subject to customary post-closing adjustments. The divestiture includes the company's In Vitro Diagnostic (IVD) PCR kits for rapid deceased donor HLA typing, IVD NGS-based kits for transplant recipient HLA typing globally, and IVD NGS-based monitoring assays for solid organ and stem cell transplant recipients outside of North America.

Strategic Impact

John Hanna, President and Chief Executive Officer of CareDx, stated that the transaction sharpens the company's focus on its core U.S. Precision Medicine Testing Services and Patient and Digital Solutions. He noted that the integrated model continues to deliver strong growth and that the sale simplifies the operating model while supporting disciplined capital allocation, including investments in high-growth areas such as specialty oncology.

Key Information

CareDx anticipates providing additional details regarding the financial impact of the transaction, including pro forma results, during its second quarter 2026 earnings call. Rothschild & Co. and Fenwick & West LLP represented CareDx, while TD Cowen and Kahn Partners represented Eurobio Scientific.

CareDx, Inc. (NASDAQ: CDNA) — The Transplant Company™, a precision medicine company focused on transplant patients, announced its participation at the American Transplant Congress (ATC) 2026. The event takes place June 20–24 in Boston, Massachusetts. The company presented data supporting AlloSure® as a clinical endpoint for risk assessment, treatment response, and long-term graft outcomes.

Real-world clinical use and scientific advancements involving AlloSure Kidney, AlloSure Plus, HistoMap Kidney, HeartCare (AlloMap Heart and AlloSure Heart), and AlloSure Lung were featured in more than 30 abstracts and 9 oral presentations. The data were generated from studies at over 110 transplant centers across the United States. The findings reflect the continued evolution of AlloSure dd-cfDNA from an emerging biomarker to a potential clinical endpoint.

Dr. Jeffrey Teuteberg, Chief Medical Officer of CareDx, stated that the data indicate a shift where AlloSure is being explored to evaluate treatment response, stratify risk, and predict graft outcomes. He noted that this has implications for patient management and clinical trial design. The company also presented work on spatial transcriptomics to provide insights into immune activation and injury.

Key Study Findings in Kidney Transplantation

Studies demonstrated the prognostic value of early AlloSure monitoring. Persistent elevation in the first four months after kidney transplantation was associated with higher rates of rejection, de novo DSA, eGFR decline, and graft loss at three years. Transient elevations that normalized showed outcomes comparable to consistently low levels.

In a study of tocilizumab for antibody-mediated rejection, AlloSure levels remained elevated over 12 months despite reductions in DSA and stabilization of eGFR. This correlated with persistent histologic AMR on follow-up biopsy. A multicenter analysis of more than 4,000 kidney transplant recipients found elevated AlloSure was independently associated with microvascular inflammation (MVI) phenotypes, including DSA-negative, C4d-negative MVI.

AlloSure Plus scores were significantly higher in biopsy-confirmed acute cellular rejection (ACR) and antibody-mediated rejection (AMR) compared to no rejection. The scores showed an AUROC of 0.79 for discriminating rejection.

Next-Generation Biomarker Discovery

HistoMap Kidney molecular analysis classified the majority of biopsies with isolated arteritis (v-lesions) as "No Rejection." This suggests that isolated arteritis may not represent active T-cell-mediated rejection. The integration of single-cell and spatial transcriptomics via ImmuneScape™ revealed distinct immune cell populations and spatial immune infiltration patterns associated with kidney allograft rejection.

Key Study Findings in Heart Transplantation

In heart transplantation, higher AlloMap scores were significantly associated with subsequent elevations in AlloSure Heart. The risk increased at gene expression profiling (GEP) scores ≥25. This supports AlloMap as an early indicator of immune activation that may precede graft injury detected by dd-cfDNA alone.

Patients initiated on mammalian target of rapamycin inhibitor (mTORi) showed increased evidence of molecular rejection as detected by HeartCare. The data suggest more frequent non-invasive monitoring may be warranted in this population.

New Study Finding in Multiorgan Transplantation

HeartCare was routinely incorporated in post-transplant follow-up for simultaneous heart-kidney transplant recipients. With consistent testing frequency, investigators demonstrated predictable patterns in molecular testing results.

CareDx Symposia

A panel of transplant nephrologists discussed the application of AlloSure Kidney and AlloSure Plus rejection risk assessment in clinical decision-making. The symposium featured data from the recently-published second manuscript of the Kidney Allograft Outcomes AlloSure (KOAR) registry.